Literature DB >> 23529045

Dual RAAS blockade has dual effects on outcome.

Hiddo J Lambers Heerspink, Dick de Zeeuw.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 23529045     DOI： 10.1038/nrendo.2013.65

Source DB:  PubMed          Journal:  Nat Rev Endocrinol        ISSN： 1759-5029            Impact factor:   43.330


× No keyword cloud information.
  9 in total

1.  ALTITUDE trial and dual RAS blockade: the alluring but soft science of the surrogate end point.

Authors:  Franz H Messerli; Sripal Bangalore
Journal:  Am J Med       Date:  2013-01-16       Impact factor: 4.965

2.  Prediction of coronary heart disease using risk factor categories.

Authors:  P W Wilson; R B D'Agostino; D Levy; A M Belanger; H Silbershatz; W B Kannel
Journal:  Circulation       Date:  1998-05-12       Impact factor: 29.690

3.  Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

Authors:  Wouter B A Eijkelkamp; Zhongxin Zhang; Giuseppe Remuzzi; Hans-Henrik Parving; Mark E Cooper; William F Keane; Shahnaz Shahinfar; Gilbert W Gleim; Matthew R Weir; Barry M Brenner; Dick de Zeeuw
Journal:  J Am Soc Nephrol       Date:  2007-04-04       Impact factor: 10.121

4.  Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial.

Authors:  Y Miao; D Dobre; H J Lambers Heerspink; B M Brenner; M E Cooper; H-H Parving; S Shahinfar; D Grobbee; D de Zeeuw
Journal:  Diabetologia       Date:  2010-09-30       Impact factor: 10.122

5.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

Authors:  Johannes F E Mann; Roland E Schmieder; Matthew McQueen; Leanne Dyal; Helmut Schumacher; Janice Pogue; Xingyu Wang; Aldo Maggioni; Andrzej Budaj; Suphachai Chaithiraphan; Kenneth Dickstein; Matyas Keltai; Kaj Metsärinne; Ali Oto; Alexander Parkhomenko; Leopoldo S Piegas; Tage L Svendsen; Koon K Teo; Salim Yusuf
Journal:  Lancet       Date:  2008-08-16       Impact factor: 79.321

6.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes.

Authors:  Hans-Henrik Parving; Barry M Brenner; John J V McMurray; Dick de Zeeuw; Steven M Haffner; Scott D Solomon; Nish Chaturvedi; Frederik Persson; Akshay S Desai; Maria Nicolaides; Alexia Richard; Zhihua Xiang; Patrick Brunel; Marc A Pfeffer
Journal:  N Engl J Med       Date:  2012-11-03       Impact factor: 91.245

7.  Telmisartan, ramipril, or both in patients at high risk for vascular events.

Authors:  Salim Yusuf; Koon K Teo; Janice Pogue; Leanne Dyal; Ingrid Copland; Helmut Schumacher; Gilles Dagenais; Peter Sleight; Craig Anderson
Journal:  N Engl J Med       Date:  2008-03-31       Impact factor: 91.245

8.  A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers.

Authors:  P A Smink; J Hoekman; D E Grobbee; M J C Eijkemans; H-H Parving; F Persson; H Ibsen; L Lindholm; K Wachtell; D de Zeeuw; H J Lambers Heerspink
Journal:  Eur J Prev Cardiol       Date:  2013-03-06       Impact factor: 7.804

Review 9.  Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials.

Authors:  Harikrishna Makani; Sripal Bangalore; Kavit A Desouza; Arpit Shah; Franz H Messerli
Journal:  BMJ       Date:  2013-01-28
  9 in total
  1 in total

Review 1.  Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis.

Authors:  Hiddo J Lambers Heerspink; Tobias F Kröpelin; Jarno Hoekman; Dick de Zeeuw
Journal:  J Am Soc Nephrol       Date:  2014-11-24       Impact factor: 10.121
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.